Ambeed.cn

首页 / / / / Mubritinib/木利替尼

Mubritinib/木利替尼 {[allProObj[0].p_purity_real_show]}

货号:A137400 同义名: TAK-165

Mubritinib (TAK-165) 是一种有效且选择性的 EGFR2/HER2 抑制剂,IC50 值为 6 nM。 PACMA 31 是一种不可逆的口服蛋白质二硫异构酶 (PDI) 抑制剂,IC50 为 10 μM。 Tavapadon (PF-06649751) 是一种口服活性、高选择性的多巴胺 D1/D5 受体部分激动剂。Tavapadon 有效促进运动和减少残疾,显示出治疗帕金森病的潜力。

Mubritinib/木利替尼 化学结构 CAS号:366017-09-6
Mubritinib/木利替尼 化学结构
CAS号:366017-09-6
Mubritinib/木利替尼 3D分子结构
CAS号:366017-09-6
Mubritinib/木利替尼 化学结构 CAS号:366017-09-6
Mubritinib/木利替尼 3D分子结构 CAS号:366017-09-6
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Mubritinib/木利替尼 纯度/质量文件 产品仅供科研

货号:A137400 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Adv. Funct. Mater., 2025, 2500696. Ambeed. [ A245395 ]
JACS, 2025. Ambeed. [ A505336 ]
Sci. Adv., 2025, 11(13): eadr0006. Ambeed. [ A152627 ]
ACS Appl. Mater. Interfaces, 2025, 17(12): 18046-18058. Ambeed. [ A739356 , A171817 ]
Food Res. Int., 2025, 116191. Ambeed. [ A1452012 ]
更多 >
产品名称 HER2 其他靶点 纯度
Poziotinib ++++

HER2, IC50: 5.3 nM

98%
Tyrphostin AG 879 +

HER2-Neu, IC50: 1.0 μM

95%
TAK-285 +

HER2, IC50: 17 nM

99%+
ARRY-380 analog 99%
Canertinib +++

ErbB2, IC50: 9.0 nM

EGFR 99%+
(E/Z)-CP-724714 ++

HER2/ErbB2, IC50: 10 nM

98+%
Lapatinib +++

ErbB2, IC50: 9.2 nM

EGFR 98%
AEE788 ++++

HER2/ErbB2, IC50: 6 nM

EGFR 98+%
Neratinib +

HER2, IC50: 59 nM

EGFR,Src 98%
BMS-599626 +

HER2, IC50: 30 nM

98%
Mubritinib ++++

HER2/ErbB2, IC50: 6.0 nM

99%+
Tucatinib +++

ErbB2, IC50: 8 nM

98%
Sapitinib ++++

ErbB2, IC50: 3 nM

EGFR 99%+
CUDC-101 ++

HER2, IC50: 15.7 nM

HDAC,EGFR 99%+
Afatinib dimaleate ++

HER2, IC50: 14 nM

98%
Afatinib ++

HER2, IC50: 14 nM

99%
Pertuzumab 95%
Trastuzumab 99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Mubritinib/木利替尼 生物活性

靶点
  • HER2

    HER2/ErbB2, IC50:6.0 nM

描述 Human epidermal growth factor receptor (EGFR; HER1,erbB1), human epidermal growth factor r eceptor 2 (HER2; erbB2), HER3 (erbB3) and HER4 (erbB4) are members of the ErbB family of transmembrane receptor tyrosine kinases. Among them, HER2 is a validated and high-value target. Overexpression of HER2 occurs in gastric, colorectal, NSCLC, breast and ovarian cancers. Mubritinib is a highly selective Her2 inhibitor with IC50 value of 6nM (measured by tyrosine-kinase activity), with almost no inhibition of other related target including EGFR, FGFR, PDGFR, Jak1, Src and Blk (all IC50 values>25000nM). Treatment with mubritinib at concentration>0.1μM for 2h caused significant decrease of autophosphorylation of Her2, as well as phosphorylation level of the key signal transduction mediator AKT and MAPK, in BT474 cells overexpressing HER2. The sensitivity of cell to Mubritinib depended on HER2 levels, as BT474 cells over-expressing HER2 strongly with highly sensitivity to Mubritinib (IC50=0.005µM), PC-3 cells expressing HER2 very weakly with less sensitive to Mubritinib (IC50=4.62µM), and HT1376 and ACHN cells over-expressed EGFR with much higher IC50 values (>25μM). Oral administration of 20mg/kg Mubritinib twice daily for 2 weeks significantly inhibited tumor growth in UMUC-3 bladder cancer model, as well as LN-REC4 prostate cancer model at dose of 10 or 20mg/kg[1].

Mubritinib/木利替尼 动物研究

Dose Mice[1] (p.o.): 10 m/kg, 20 mg/kg
Administration p.o.

Mubritinib/木利替尼 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00034281 Breast Neoplasm ... 展开 >> Pancreatic Neoplasm Lung Neoplasm Ovarian Neoplasm Renal Neoplasm 收起 << Phase 1 Completed - United States, Arizona ... 展开 >> Arizona Cancer Center Scottsdale, Arizona, United States, 85258 United States, Texas The Institute for Drug Development San Antonio, Texas, United States, 78229 Brooke Army Medical Center/Drug Development Unit San Antonio, Texas, United States, 78234 South Texas VA, Audie Murphy Division San Antonio, Texas, United States, 78284 收起 <<

Mubritinib/木利替尼 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.13mL

0.43mL

0.21mL

10.67mL

2.13mL

1.07mL

21.35mL

4.27mL

2.13mL

Mubritinib/木利替尼 技术信息

CAS号366017-09-6
分子式C25H23F3N4O2
分子量 468.47
SMILES Code FC(F)(C1=CC=C(/C=C/C2=NC(COC3=CC=C(C=C3)CCCCN4C=CN=N4)=CO2)C=C1)F
MDL No. MFCD09954135
别名 TAK-165
运输蓝冰
InChI Key ZTFBIUXIQYRUNT-MDWZMJQESA-N
Pubchem ID 6444692
存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Sealed in dry, 2-8°C

溶解方案

DMSO: 50 mg/mL(106.73 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方

IP 2% DMSO+2% Tween80+40% PEG300+water 2 mg/mL clear

PO 0.5% CMC-Na 18 mg/mL suspension

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。